The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

The White House says President Trump underwent a medical exam because of swelling in his legs and has been diagnosed with a ...

With the launch, Anumana became the first organization to utilize the marketplace. Philips now plans to make offer the ...

NewYork-Presbyterian researchers have developed a deep learning model that increases doctors' abilities to diagnose ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

A new study shows that people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction) are ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...